The dose-response data broke down as follows: 1mg dose: 8.7% average weight loss at 48 weeks 4mg dose: 15.2% average weight loss at 48 weeks 8mg dose: 21.1% average weight loss at 48 weeks 12mg dose: 24.2% average weight loss at 48 weeks Placebo: 2.1% average weight loss at 48 weeks The week-by-week progression told an equally compelling story
Im Gegensatz zu reinen GLP-1-Agonisten wie Semaglutid oder Dualagonisten wie Tirzepatid aktiviert Retatrutid gleichzeitig drei Rezeptoren: den Glucagon-hnlichen Peptid-1-Rezeptor (GLP-1R), den Glukose-abhngigen insulinotropen Polypeptidrezeptor (GIPR) und den Glucagonrezeptor (GCGR)
- Which GLP-1 medication would be the best option for me
What they found: Mean weight loss: 2.6 kg vs 2.3 kg placebo , a difference of only 0.3 kg (1 %) Statistically non-significant Clinically unsatisfactory for the obesity indication Safety profile remained favorable Why it matters: The study stopped the development of AOD-9604 as a drug
Early weeks show similar results across all three medications
Different forms of Semaglutide DMFs exist exist since differing nations have different regulations, such as Semaglutide USDMF, ASMF (EDMF), JDMF, CDMF, etc
